Johnson & Johnson (JNJ) Expected to Announce Quarterly Earnings on Wednesday

Johnson & Johnson (NYSE:JNJ) is expected to issue its Q4 2025 results before the market opens on Wednesday, January 21st. Analysts expect the company to announce earnings of $2.53 per share and revenue of $24.1368 billion for the quarter. Investors can check the company’s upcoming Q4 2025 earning summary page for the latest details on the call scheduled for Wednesday, January 21, 2026 at 8:30 AM ET.

Johnson & Johnson Stock Down 0.3%

Johnson & Johnson stock opened at $218.81 on Tuesday. The company has a current ratio of 1.07, a quick ratio of 0.80 and a debt-to-equity ratio of 0.50. Johnson & Johnson has a 1-year low of $141.50 and a 1-year high of $220.11. The firm’s fifty day simple moving average is $206.43 and its 200-day simple moving average is $187.62. The company has a market capitalization of $527.18 billion, a P/E ratio of 21.12, a P/E/G ratio of 2.25 and a beta of 0.34.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.4%. Johnson & Johnson’s payout ratio is currently 50.19%.

Wall Street Analysts Forecast Growth

JNJ has been the topic of a number of recent analyst reports. Johnson Rice set a $190.00 price objective on Johnson & Johnson and gave the company a “hold” rating in a research note on Wednesday, October 22nd. HSBC reiterated a “buy” rating and set a $240.00 price target on shares of Johnson & Johnson in a report on Wednesday, December 10th. Royal Bank Of Canada set a $240.00 price objective on shares of Johnson & Johnson in a report on Wednesday, December 17th. Wall Street Zen lowered shares of Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Saturday. Finally, Citigroup raised their price target on Johnson & Johnson from $215.00 to $232.00 and gave the company a “buy” rating in a research report on Thursday, December 11th. Four research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and an average target price of $213.33.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Analysts are becoming more constructive on JNJ heading into 2026, citing improving fundamentals and durable cash flow that support the dividend and valuation. Analysts Turn More Constructive on Johnson & Johnson
• Positive Sentiment: Zacks highlights J&J alongside other large names and notes strong pharma and MedTech momentum, which could underpin revenue growth and investor confidence heading into earnings. Zacks Investment Ideas feature highlights
• Positive Sentiment: JNJ continues to be recommended as a dividend holding in retail investor lists, reinforcing demand from income?oriented investors given its yield and payout consistency. 3 Dividend Stocks to Own
• Neutral Sentiment: Multiple pre?earnings analyst pieces (TipRanks, Zacks) note JNJ’s Q4 revenue expectations (~$24.16B, roughly +7% YoY) and discuss positioning strategies for investors who want exposure but want to limit risk ahead of the print. Is JNJ Stock a Buy Ahead of Q4?
• Neutral Sentiment: Zacks’ Q&A on buy/hold/sell frames JNJ as a mixed case: strong product momentum but headline risk into the report — useful context but not a direct catalyst. Should You Buy, Sell or Hold J&J Ahead of Q4?
• Negative Sentiment: Seeking Alpha warns J&J is tempering expectations after a sizable 2025 downgrade, highlighting margin and growth pressures that could weigh on sentiment if management echoes lowered guidance. Tempering Expectations After A Massive 2025
• Negative Sentiment: Zacks and other previews call out near?term headwinds: Stelara biosimilar competition and China market pressures that could blunt top?line growth and weigh on the print. Buy/Sell/Hold Preview
• Negative Sentiment: Bank of America maintained a Hold rating, signaling limited near?term upside in analyst coverage and possibly contributing to cautious positioning. Bank of America Sticks to Hold

Hedge Funds Weigh In On Johnson & Johnson

Hedge funds and other institutional investors have recently made changes to their positions in the business. Intrepid Capital Management Inc. raised its position in Johnson & Johnson by 0.4% in the third quarter. Intrepid Capital Management Inc. now owns 12,785 shares of the company’s stock worth $2,371,000 after purchasing an additional 54 shares in the last quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. raised its holdings in shares of Johnson & Johnson by 0.3% in the 3rd quarter. Holt Capital Advisors L.L.C. dba Holt Capital Partners L.P. now owns 19,003 shares of the company’s stock worth $3,524,000 after buying an additional 60 shares in the last quarter. Semmax Financial Advisors Inc. lifted its position in shares of Johnson & Johnson by 55.0% during the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the period. WealthCollab LLC boosted its stake in Johnson & Johnson by 9.9% in the 2nd quarter. WealthCollab LLC now owns 924 shares of the company’s stock valued at $141,000 after buying an additional 83 shares in the last quarter. Finally, Rakuten Securities Inc. raised its stake in Johnson & Johnson by 8.0% during the second quarter. Rakuten Securities Inc. now owns 1,140 shares of the company’s stock worth $174,000 after acquiring an additional 84 shares in the last quarter. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Company Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.